Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2024

Genmab — November 2024

Planlagt Fastgjort Låst Flyttet Genmab
724 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #712

    After ProfoundBio buy, Genmab open to more M&A if it makes 'strategic sense,’ CFO says https://www.fiercebiotech.com/biotech/after-profoundbio-buy-genmab-open-further-ma-make-strategic-sense-says-cfo

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #713

      (Link kræver ikke abonnement)

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #714

        Der sker noget på M&A fronten. Roche køber lidt Car-t til en præmium på +200% https://finance.yahoo.com/quote/PSTX/

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #715

          Nykredit var i sin morgenkommentar i går ude at sige "Baseret på de foreløbige data er det vores vurdering, at Janssen vil udnytte optionen på GEN3014, hvilket vil sende både optionsbetalingen (150 mio USD) og udviklingsmilepæl (op til 125 mio. USD) og potentielt set betydelige fremtidige royaltybetalnger til Genmab". De fastholder køb og kurs 2300.

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #716

            Roche's TIGIT prospect fails another phase 3 lung cancer test https://www.fiercebiotech.com/biotech/roches-tigit-prospect-fails-another-phase-3-lung-cancer-test

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #717

              Nyt fase 3: A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA) (MASCOT)

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #718

                https://clinicaltrials.gov/study/NCT06706622?term=af82422&checkSpell=&rank=2

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #719

                  Lundbeck slightly ahead of schedule then i guess, last i saw it was planned at the beginning of 2025

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #720

                    A throng of new medicines hit the Japanese market on November 20 upon their reimbursement listing, including Amgen’s Tepezza (teprotumumab) .... https://pj.jiho.jp/article/252053

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #721

                      Genmab er blandt de nævnte"Analyti­kere: Disse fem C25-aktier ses stige over 50 pct." https://borsen.dk/nyheder/investor/analytikere-disse-fem-c25-aktier-ses-stige-over-50-pct?b_source=borsen&b_medium=row_0&b_campaign=news_3&utm_source=nyhedsbrev&utm_medium=email&utm_campaign=28.11.24-morningbrief&utm_placement=10&utm_batch=38674800402c9db#newsletter

                      1 Reply Last reply
                      0
                      • concilladoC Offline
                        concilladoC Offline
                        concillado
                        wrote on sidst redigeret af
                        #722

                        Ud fra kurshistorikken, så kunne de bare ændre titlen for Genmabs vedkommende til 100 pct. 😉

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #723

                          Genmab/SHB: Skærer kursmål og gentager "market perform" https://proinvestor.com/investornyt/1248292/genmab-shb-skaerer-kursmal-og-gentager-market-perform

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #724

                            Det levner så plads til en stigning på ca 33% ud fra den aktuelle kurs.

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #725

                              Børsen - FEM C25-AKTIER SES STIGE OVER 50 PCT.

                              Analytikerne peger på fem C25-aktier med særligt stort kurspotentiale efter den danske regnskabssæson. Det er Vestas, GN Store Nord, Torm, Bavarian Nordic og Genmab. (Side 37)

                              1 Reply Last reply
                              0

                              Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                              Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                              With your input, this post could be even better 💗

                              Tilmeld Log ind
                              Svar
                              • Svar som emne
                              Login for at svare
                              • Ældste til nyeste
                              • Nyeste til ældste
                              • Most Votes


                              • Log ind

                              • Har du ikke en konto? Tilmeld

                              • Login or register to search.
                              Powered by NodeBB Contributors
                              • First post
                                Last post
                              0
                              • Kategorier
                              • Seneste
                              • Etiketter
                              • Populære
                              • Verden
                              • Bruger
                              • Grupper